Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Meanwhile, the federal government last week told the appeals court that the district judge erred in November 2021 when she told federal health officials to assess whether the 340B statute forces them to let all providers have a limitless number of contract pharmacies, or whether under the statute they can set different limits for different types of providers.
Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
